Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

Turn £10k Into £18.5k With GlaxoSmithKline plc

Even during a troubled decade, GlaxoSmithKline plc (LON: GSK) shares have performed reasonably.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskI took a look recently at AstraZeneca, and was impressed to see an overall trebling in value over the past 10 years if all dividends were reinvested.

The FTSE 100‘s other big pharmaceuticals company, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) hasn’t been doing quite so well — for one thing, it hasn’t had its shares boosted by takeover fever.

A 20% gain?

If you’d invested £10,000 in GlaxoSmithKline shares 10 years ago, you’d have been paying around 1,191p apiece — and at that price you could have bagged 839 shares (ignoring dealing costs).

Now, the share price has only gained 21.5% over the period, and your ten grand would have grown to £12,149. While that might have matched cash in a savings account, we really expect better from investing in shares.

But that doesn’t include dividends, so what would those have added?

Rising dividends

GlaxoSmithKline has actually been paying pretty decent dividends, starting the period offering yields of around 3.5%. But that started ramping up in 2007 as the share price fell a little, reaching 5% by 2009 — and yields have remained close to that level since. 

One thing that does mean is that dividends alone would have easily been enough to beat cash sitting in the bank, without any share price gain!

Earnings per share (EPS) can be a little volatile, but even when EPS didn’t cover the dividend in 2010, Glaxo maintained the cash payment from its own resources — and EPS was back up to normal the next year.

Another five grand!

In total, GlaxoSmithKline would have paid you an extra £4,971 in dividends, taking your total to £17,120 — and a 71% rise is starting to look reasonable.

But what if, instead of taking and spending your cash handout each year, you had reinvested it in more Glaxo shares?

Before we look at that, let me mention a thing called pound cost averaging — it’s a fancy term that just means you’ll get more shares for the same money over a period when the price dips and recovers than if it had remained flat.

For Glaxo, what that means is that you’d have added just 24 new shares at the end of 2004 when the price was around 1,440p, but by 2007 when it had dropped to 1,210p you’d have scooped up 40 of them.

A decent result

Anyway, with dividends reinvested, you’d be ending the decade with £18,594 — and an 85.5% gain is really nothing to be sniffed at, especially for a share that has actually lagged the FTSE a little over the period (but with better than average dividend yields).

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the strong IAG share price surge 69% in 2026?

IAG's share price has been one of the FTSE 100's best performers this year. Royston Wild considers if it might…

Read more »

Rolls-Royce Hydrogen Test Rig at Loughborough University
Investing Articles

I asked ChatGPT for a discounted cash flow on the Rolls-Royce share price. Here’s what it said…

Out of curiosity, James Beard used artificial intelligence software to see whether it thinks the Rolls-Royce share price is fairly…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

This FTSE 100 CEO just spent £1m buying 30,000 shares!

Company insiders of this FTSE 100 investing giant have been ‘buying the dip’ with almost £5m worth of shares purchased…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

With a 10-year annualised return of 26%, this growth stock could be too good to ignore

With consistent demand for its products, Diploma has managed to achieve average returns far above most other FTSE 100 stocks.…

Read more »

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

In 2025, the Marks and Spencer share price has turned £5,000 into…

2025 has been a poor year for the Marks and Spencer share price. However, Edward Sheldon believes that it can…

Read more »

Investing Articles

3 FTSE 100 predictions for 2026

2025 has been a blockbuster year for the FTSE 100. Here’s what Edward Sheldon thinks will happen with the stock…

Read more »

Young woman holding up three fingers
Investing Articles

Want to start investing in 2026? 3 things to get ready now!

Before someone is ready to start investing in the stock market, our writer reckons it could well be worth them…

Read more »

Investing Articles

Can the stock market continue its strong performance into 2026?

Will the stock market power ahead next year -- or could its recent strong run come crashing down? Christopher Ruane…

Read more »